HKMPY
Price
$53.14
Change
-$1.27 (-2.33%)
Updated
Jul 16 closing price
Capitalization
5.93B
HROW
Price
$36.14
Change
+$1.59 (+4.60%)
Updated
Jul 17 closing price
Capitalization
467.85M
25 days until earnings call
Interact to see
Advertisement

HKMPY vs HROW

Header iconHKMPY vs HROW Comparison
Open Charts HKMPY vs HROWBanner chart's image
Hikma Pharmaceuticals
Price$53.14
Change-$1.27 (-2.33%)
Volume$384
Capitalization5.93B
Harrow
Price$36.14
Change+$1.59 (+4.60%)
Volume$573.94K
Capitalization467.85M
HKMPY vs HROW Comparison Chart in %
Loading...
HKMPY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HKMPY vs. HROW commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HKMPY is a Hold and HROW is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (HKMPY: $53.14 vs. HROW: $36.14)
Brand notoriety: HKMPY and HROW are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: HKMPY: 45% vs. HROW: 136%
Market capitalization -- HKMPY: $5.93B vs. HROW: $467.85M
HKMPY [@Pharmaceuticals: Other] is valued at $5.93B. HROW’s [@Pharmaceuticals: Other] market capitalization is $467.85M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HKMPY’s FA Score shows that 1 FA rating(s) are green whileHROW’s FA Score has 1 green FA rating(s).

  • HKMPY’s FA Score: 1 green, 4 red.
  • HROW’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than HKMPY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HKMPY’s TA Score shows that 3 TA indicator(s) are bullish while HROW’s TA Score has 4 bullish TA indicator(s).

  • HKMPY’s TA Score: 3 bullish, 5 bearish.
  • HROW’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, HROW is a better buy in the short-term than HKMPY.

Price Growth

HKMPY (@Pharmaceuticals: Other) experienced а -0.49% price change this week, while HROW (@Pharmaceuticals: Other) price change was +15.21% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.97%. For the same industry, the average monthly price growth was +6.36%, and the average quarterly price growth was +73.05%.

Reported Earning Dates

HKMPY is expected to report earnings on Mar 19, 2025.

HROW is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-0.97% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HKMPY($5.93B) has a higher market cap than HROW($468M). HROW has higher P/E ratio than HKMPY: HROW (39.53) vs HKMPY (32.15). HKMPY YTD gains are higher at: 8.181 vs. HROW (7.720). HKMPY has higher annual earnings (EBITDA): 489M vs. HROW (9.95M). HKMPY has more cash in the bank: 292M vs. HROW (82.8M). HROW has less debt than HKMPY: HROW (191M) vs HKMPY (1.28B). HKMPY has higher revenues than HROW: HKMPY (2.52B) vs HROW (130M).
HKMPYHROWHKMPY / HROW
Capitalization5.93B468M1,268%
EBITDA489M9.95M4,913%
Gain YTD8.1817.720106%
P/E Ratio32.1539.5381%
Revenue2.52B130M1,936%
Total Cash292M82.8M353%
Total Debt1.28B191M672%
FUNDAMENTALS RATINGS
HKMPY vs HROW: Fundamental Ratings
HKMPY
HROW
OUTLOOK RATING
1..100
8570
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
10047
SMR RATING
1..100
9297
PRICE GROWTH RATING
1..100
5641
P/E GROWTH RATING
1..100
9210
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HKMPY's Valuation (17) in the null industry is somewhat better than the same rating for HROW (79) in the Pharmaceuticals Other industry. This means that HKMPY’s stock grew somewhat faster than HROW’s over the last 12 months.

HROW's Profit vs Risk Rating (47) in the Pharmaceuticals Other industry is somewhat better than the same rating for HKMPY (100) in the null industry. This means that HROW’s stock grew somewhat faster than HKMPY’s over the last 12 months.

HKMPY's SMR Rating (92) in the null industry is in the same range as HROW (97) in the Pharmaceuticals Other industry. This means that HKMPY’s stock grew similarly to HROW’s over the last 12 months.

HROW's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as HKMPY (56) in the null industry. This means that HROW’s stock grew similarly to HKMPY’s over the last 12 months.

HROW's P/E Growth Rating (10) in the Pharmaceuticals Other industry is significantly better than the same rating for HKMPY (92) in the null industry. This means that HROW’s stock grew significantly faster than HKMPY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HKMPYHROW
RSI
ODDS (%)
Bullish Trend 1 day ago
57%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
47%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
50%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
58%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
57%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
N/A
Bullish Trend 1 day ago
84%
Declines
ODDS (%)
Bearish Trend 15 days ago
63%
Bearish Trend 10 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
42%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
HKMPY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JHML74.250.49
+0.66%
JHancock Multifactor Large Cap ETF
MPRO29.720.10
+0.34%
Monarch ProCap ETF
RZC25.460.08
+0.32%
Reinsurance Group of America
FLMX29.300.04
+0.14%
Franklin FTSE Mexico ETF
ROIS50.12N/A
N/A
Hartford Multifactor International Small Company ETF

HKMPY and

Correlation & Price change

A.I.dvisor tells us that HKMPY and HROW have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HKMPY and HROW's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HKMPY
1D Price
Change %
HKMPY100%
N/A
HROW - HKMPY
23%
Poorly correlated
+4.60%
PAIOF - HKMPY
22%
Poorly correlated
N/A
CXXIF - HKMPY
22%
Poorly correlated
+8.92%
HYPMY - HKMPY
14%
Poorly correlated
-7.52%
ETST - HKMPY
10%
Poorly correlated
+1.22%
More

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AMRX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
+4.60%
AMRX - HROW
46%
Loosely correlated
-0.24%
EBS - HROW
38%
Loosely correlated
+4.15%
OGI - HROW
34%
Loosely correlated
N/A
AMPH - HROW
32%
Poorly correlated
+2.02%
VTRS - HROW
32%
Poorly correlated
+2.09%
More